PortfoliosLab logo
PRCT vs. PSEC
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between PRCT and PSEC is 0.54, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.5

Performance

PRCT vs. PSEC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in PROCEPT BioRobotics Corporation (PRCT) and Prospect Capital Corporation (PSEC). The values are adjusted to include any dividend payments, if applicable.

0.00%50.00%100.00%December2025FebruaryMarchAprilMay
32.62%
-31.48%
PRCT
PSEC

Key characteristics

Sharpe Ratio

PRCT:

0.07

PSEC:

-0.74

Sortino Ratio

PRCT:

0.72

PSEC:

-0.84

Omega Ratio

PRCT:

1.08

PSEC:

0.87

Calmar Ratio

PRCT:

0.10

PSEC:

-0.49

Martin Ratio

PRCT:

0.22

PSEC:

-1.46

Ulcer Index

PRCT:

22.61%

PSEC:

14.56%

Daily Std Dev

PRCT:

65.16%

PSEC:

28.82%

Max Drawdown

PRCT:

-63.51%

PSEC:

-61.56%

Current Drawdown

PRCT:

-44.07%

PSEC:

-40.82%

Fundamentals

Market Cap

PRCT:

$3.05B

PSEC:

$1.60B

EPS

PRCT:

-$1.69

PSEC:

-$0.21

PS Ratio

PRCT:

12.24

PSEC:

2.02

PB Ratio

PRCT:

7.83

PSEC:

0.47

Total Revenue (TTM)

PRCT:

$249.12M

PSEC:

$372.02M

Gross Profit (TTM)

PRCT:

$154.96M

PSEC:

$179.62M

EBITDA (TTM)

PRCT:

-$80.65M

PSEC:

$152.08M

Returns By Period

In the year-to-date period, PRCT achieves a -30.92% return, which is significantly lower than PSEC's -12.74% return.


PRCT

YTD

-30.92%

1M

8.57%

6M

-39.73%

1Y

-13.51%

5Y*

N/A

10Y*

N/A

PSEC

YTD

-12.74%

1M

-1.50%

6M

-25.22%

1Y

-21.59%

5Y*

9.74%

10Y*

3.70%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

PRCT vs. PSEC — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PRCT
The Risk-Adjusted Performance Rank of PRCT is 5454
Overall Rank
The Sharpe Ratio Rank of PRCT is 5353
Sharpe Ratio Rank
The Sortino Ratio Rank of PRCT is 5656
Sortino Ratio Rank
The Omega Ratio Rank of PRCT is 5252
Omega Ratio Rank
The Calmar Ratio Rank of PRCT is 5555
Calmar Ratio Rank
The Martin Ratio Rank of PRCT is 5353
Martin Ratio Rank

PSEC
The Risk-Adjusted Performance Rank of PSEC is 1313
Overall Rank
The Sharpe Ratio Rank of PSEC is 1212
Sharpe Ratio Rank
The Sortino Ratio Rank of PSEC is 1515
Sortino Ratio Rank
The Omega Ratio Rank of PSEC is 1212
Omega Ratio Rank
The Calmar Ratio Rank of PSEC is 1919
Calmar Ratio Rank
The Martin Ratio Rank of PSEC is 88
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

PRCT vs. PSEC - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for PROCEPT BioRobotics Corporation (PRCT) and Prospect Capital Corporation (PSEC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for PRCT, currently valued at 0.07, compared to the broader market-2.00-1.000.001.002.003.00
PRCT: 0.07
PSEC: -0.74
The chart of Sortino ratio for PRCT, currently valued at 0.72, compared to the broader market-6.00-4.00-2.000.002.004.00
PRCT: 0.72
PSEC: -0.84
The chart of Omega ratio for PRCT, currently valued at 1.08, compared to the broader market0.501.001.502.00
PRCT: 1.08
PSEC: 0.87
The chart of Calmar ratio for PRCT, currently valued at 0.10, compared to the broader market0.001.002.003.004.005.00
PRCT: 0.10
PSEC: -0.49
The chart of Martin ratio for PRCT, currently valued at 0.22, compared to the broader market-10.000.0010.0020.00
PRCT: 0.22
PSEC: -1.46

The current PRCT Sharpe Ratio is 0.07, which is higher than the PSEC Sharpe Ratio of -0.74. The chart below compares the historical Sharpe Ratios of PRCT and PSEC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2025FebruaryMarchAprilMay
0.07
-0.74
PRCT
PSEC

Dividends

PRCT vs. PSEC - Dividend Comparison

PRCT has not paid dividends to shareholders, while PSEC's dividend yield for the trailing twelve months is around 17.50%.


TTM20242023202220212020201920182017201620152014
PRCT
PROCEPT BioRobotics Corporation
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
PSEC
Prospect Capital Corporation
17.50%16.01%12.02%10.30%9.27%13.31%11.18%11.41%13.45%11.98%14.72%16.05%

Drawdowns

PRCT vs. PSEC - Drawdown Comparison

The maximum PRCT drawdown since its inception was -63.51%, roughly equal to the maximum PSEC drawdown of -61.56%. Use the drawdown chart below to compare losses from any high point for PRCT and PSEC. For additional features, visit the drawdowns tool.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%December2025FebruaryMarchAprilMay
-44.07%
-40.82%
PRCT
PSEC

Volatility

PRCT vs. PSEC - Volatility Comparison

PROCEPT BioRobotics Corporation (PRCT) has a higher volatility of 21.27% compared to Prospect Capital Corporation (PSEC) at 15.31%. This indicates that PRCT's price experiences larger fluctuations and is considered to be riskier than PSEC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%December2025FebruaryMarchAprilMay
21.27%
15.31%
PRCT
PSEC

Financials

PRCT vs. PSEC - Financials Comparison

This section allows you to compare key financial metrics between PROCEPT BioRobotics Corporation and Prospect Capital Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


-100.00M0.00100.00M200.00M300.00M20212022202320242025
69.16M
148.60M
(PRCT) Total Revenue
(PSEC) Total Revenue
Values in USD except per share items

PRCT vs. PSEC - Profitability Comparison

The chart below illustrates the profitability comparison between PROCEPT BioRobotics Corporation and Prospect Capital Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-100.0%-50.0%0.0%50.0%100.0%20212022202320242025
63.9%
10.0%
(PRCT) Gross Margin
(PSEC) Gross Margin
PRCT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, PROCEPT BioRobotics Corporation reported a gross profit of 44.16M and revenue of 69.16M. Therefore, the gross margin over that period was 63.9%.
PSEC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Prospect Capital Corporation reported a gross profit of 14.82M and revenue of 148.60M. Therefore, the gross margin over that period was 10.0%.
PRCT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, PROCEPT BioRobotics Corporation reported an operating income of -27.44M and revenue of 69.16M, resulting in an operating margin of -39.7%.
PSEC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Prospect Capital Corporation reported an operating income of 49.56M and revenue of 148.60M, resulting in an operating margin of 33.4%.
PRCT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, PROCEPT BioRobotics Corporation reported a net income of -24.74M and revenue of 69.16M, resulting in a net margin of -35.8%.
PSEC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Prospect Capital Corporation reported a net income of -66.00K and revenue of 148.60M, resulting in a net margin of -0.0%.